Literature DB >> 24409447

Tumor immunology: multidisciplinary science driving basic and clinical advances.

Bridget P Keenan, Elizabeth M Jaffee, Todd D Armstrong.   

Abstract

The fourth AACR Special Conference "Tumor Immunology: Basic and Clinical Advances" was held in Miami, FL in December 2012. The overall objective of this meeting was to discuss emerging concepts in cancer immunology and immunotherapy. The key findings that emerged from this meeting included: (i) multiple immune checkpoints should be inhibited to increase effective T-cell therapy, (ii) successful adoptive T-cell therapy will rely on obtaining the proper T-cell phenotype, (iii) chimeric antigen receptors have shown promise in treating some B-cell malignancies, and (iv) multiple pathways of inflammation within the tumor microenvironment are immunotherapy targets. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 24409447      PMCID: PMC3882090          DOI: 10.1158/2326-6066.CIR-13-0011

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  63 in total

Review 1.  Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.

Authors:  Shailender Bhatia; Olga Afanasiev; Paul Nghiem
Journal:  Curr Oncol Rep       Date:  2011-12       Impact factor: 5.075

2.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase.

Authors:  Mee Young Chang; Courtney Smith; James B DuHadaway; Jennifer R Pyle; Janette Boulden; Alejandro Peralta Soler; Alexander J Muller; Lisa D Laury-Kleintop; George C Prendergast
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

4.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

5.  Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Authors:  Chrystal U Louis; Karin Straathof; Catherine M Bollard; Sravya Ennamuri; Claudia Gerken; Teresita T Lopez; M Helen Huls; Andrea Sheehan; Meng-Fen Wu; Hao Liu; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

6.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

7.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.

Authors:  Melissa M Berrien-Elliott; Stephanie R Jackson; Jennifer M Meyer; Craig J Rouskey; Thanh-Long M Nguyen; Hideo Yagita; Philip D Greenberg; Richard J DiPaolo; Ryan M Teague
Journal:  Cancer Res       Date:  2012-11-27       Impact factor: 12.701

9.  IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Authors:  Richard Metz; Sonja Rust; James B Duhadaway; Mario R Mautino; David H Munn; Nicholas N Vahanian; Charles J Link; George C Prendergast
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

10.  Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Authors:  M Jonnalagadda; C E Brown; W C Chang; J R Ostberg; S J Forman; M C Jensen
Journal:  Gene Ther       Date:  2013-01-10       Impact factor: 5.250

View more
  4 in total

1.  Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma.

Authors:  Biswajit Chakraborty; Ramkrishna Pal; Mohammed Ali; Leichombam Mohindro Singh; Dewan Shahidur Rahman; Sujit Kumar Ghosh; Mahuya Sengupta
Journal:  Cell Mol Immunol       Date:  2015-05-04       Impact factor: 11.530

Review 2.  Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.

Authors:  Nina J Chu; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2015-01-26       Impact factor: 12.531

Review 3.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603

4.  LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival.

Authors:  Yi Que; Zhixin Fang; Yuanxiang Guan; Wei Xiao; Bushu Xu; Jingjing Zhao; Huoying Chen; Xinke Zhang; Musheng Zeng; Yao Liang; Xing Zhang
Journal:  Cancer Biol Med       Date:  2019-05       Impact factor: 4.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.